METTL8: A Potential Drug Target for Various Diseases (G79828)

Target Name: METTL8

NCBI ID: G79828

METTL8

METTL8: A Potential Drug Target for Various Diseases

METTL8 (METTL8_HUMAN), also known as METTL8-ASP or METTL8-containing, is a protein that is expressed in various tissues of the human body. It is a key regulator of microtubules, which are dynamic cytoskeletal structures that play a crucial role in cell division, transport, and signaling. METTL8 has been identified as a potential drug target and has been shown to be involved in a wide range of biological processes, including cancer, neurodegenerative diseases, and developmental disorders.

METTL8 is a member of the METTL family of proteins, which are known for their ability to regulate microtubule dynamics. The METTL family consists of six proteins that share a conserved catalytic core, but differ in their N-terminus and C-terminus. METTL8 is the latest member of the family and is characterized by its N-terminus that contains a unique farnesylated cysteine residue.

METTL8 is expressed in various tissues of the human body, including the brain, spinal cord, and peripheral tissues. It is also highly expressed in cancer cells, which makes it an attractive target for cancer therapies. METTL8 has been shown to be involved in the regulation of microtubule dynamics and has been implicated in a wide range of biological processes, including cell division, neurodegenerative diseases, and developmental disorders.

One of the most significant functions of METTL8 is its role in regulating microtubule stability. Microtubules are dynamic cytoskeletal structures that play a crucial role in cell division, transport, and signaling. They are composed of a proteinaceous subunit (tubulin) and a nucleotide-binding protein (tubulin protein 1 or TP1). METTL8 is involved in the regulation of tubulin stability by interacting with the nucleotide-binding protein 2 (NBP2) and the protein destimulation of tubulin stability (DST).

METTL8 has been shown to play a role in the regulation of cell division. It has been shown to be involved in the regulation of mitosis, meiosis, and somatic cell division. METTL8 has been shown to interact with the protein casein kinase (CK) and the cyclin D1, which are involved in cell division. METTL8 has also been shown to play a role in the regulation of cell cycle progression by interacting with the protein p21 (CDK4).

METTL8 is also involved in the regulation of neurodegenerative diseases. neurodegenerative diseases are a group of progressive diseases that are characterized by the progressive loss of neurons and other cells in the nervous system. METTL8 has been shown to play a role in the regulation of neurodegenerative diseases by interacting with the protein tau (TSPT), which is involved in the regulation of microtubules.

METTL8 is also involved in the regulation of developmental disorders. developmental disorders are a group of disorders that are characterized by the progressive loss of normal cellular functions in the developing embryo. METTL8 has been shown to play a role in the regulation of developmental disorders by interacting with the protein Myrn1 (MYRNA1), which is involved in the regulation of gene expression.

In conclusion, METTL8 is a protein that is expressed in various tissues of the human body and is involved in the regulation of microtubule dynamics. It has been shown to play a role in the regulation of cell division, neurodegenerative diseases, and developmental disorders. As a potential drug target, METTL8 is a promising target for the development of new therapies for a wide range of diseases. Further research is needed to fully understand the role of METTL8 in

Protein Name: Methyltransferase 8, Methylcytidine

Functions: Mitochondrial S-adenosyl-L-methionine-dependent methyltransferase that mediates N(3)-methylcytidine modification of residue 32 of the tRNA anticodon loop of mitochondrial tRNA(Ser)(UCN) and tRNA(Thr) (PubMed:34774131, PubMed:35017528). N(3)-methylcytidine methylation modification regulates mitochondrial translation efficiency and is required for activity of the respiratory chain (PubMed:34774131, PubMed:35017528). N(3)-methylcytidine methylation of mitochondrial tRNA(Ser)(UCN) requires the formation of N(6)-dimethylallyladenosine(37) (i6A37) by TRIT1 as prerequisite (PubMed:34774131, PubMed:35017528). May also mediate N(3)-methylcytidine modification of mRNAs (PubMed:28655767). The existence of N(3)-methylcytidine modification on mRNAs is however unclear, and additional evidences are required to confirm the role of the N(3)-methylcytidine-specific mRNA methyltransferase activity of METTL8 in vivo (PubMed:34774131, PubMed:33313824)

The "METTL8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about METTL8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets